Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
XERIS BIOPHARMA HOLDINGS INC (XERS) Stock Price & Overview
NASDAQ:XERS • US98422E1038
Current stock price
6.285 USD
+0.16 (+2.53%)
Last:
The current stock price of XERS is 6.285 USD. Today XERS is up by 2.53%. In the past month the price increased by 1.41%. In the past year, price increased by 30.04%.
XERS Key Statistics
52-Week Range4.26 - 10.08
Current XERS stock price positioned within its 52-week range.
1-Month Range5.755 - 6.4099
Current XERS stock price positioned within its 1-month range.
- Market Cap
- 1.084B
- P/E
- N/A
- Fwd P/E
- 55.30
- EPS (TTM)
- -0.01
- Dividend Yield
- N/A
XERS Stock Performance
Today
+2.53%
1 Week
+2.94%
1 Month
+1.41%
3 Months
-16.78%
Longer-term
6 Months -36.86%
1 Year +30.04%
2 Years +250.00%
3 Years +171.02%
5 Years +59.92%
10 Years N/A
XERS Stock Chart
XERS Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to XERS. When comparing the yearly performance of all stocks, XERS turns out to be only a medium performer in the overall market: it outperformed 52.23% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
XERS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to XERS. There are concerns on the financial health of XERS while its profitability can be described as average.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
XERS Earnings
On March 2, 2026 XERS reported an EPS of 0.06 and a revenue of 85.81M. The company beat EPS expectations (33.69% surprise) and beat revenue expectations (2.17% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateMar 2, 2026
PeriodQ4 / 2025
EPS Reported$0.06
Revenue Reported85.807M
EPS Surprise 33.69%
Revenue Surprise 2.17%
XERS Forecast & Estimates
13 analysts have analysed XERS and the average price target is 11.37 USD. This implies a price increase of 80.84% is expected in the next year compared to the current price of 6.285.
For the next year, analysts expect an EPS growth of 1236.59% and a revenue growth 33.39% for XERS
Analysts
Analysts84.62
Price Target11.37 (80.91%)
EPS Next Y1236.59%
Revenue Next Year33.39%
XERS Index Membership
XERS is currently included in the following stock indexes tracked on ChartMill.
XERS Financial Highlights
Over the last trailing twelve months XERS reported a non-GAAP Earnings per Share(EPS) of -0.01. The EPS increased by 97.37% compared to the year before.
Income Statements
Revenue(TTM)291.85M
Net Income(TTM)554.00K
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.19% | ||
| ROA | 0.14% | ||
| ROE | 4.05% | ||
| Debt/Equity | 16.1 |
Chartmill High Growth Momentum
EPS Q2Q%300%
Sales Q2Q%42.78%
EPS 1Y (TTM)97.37%
Revenue 1Y (TTM)43.72%
XERS Ownership
Ownership
Inst Owners59.19%
Shares172.43M
Float165.86M
Ins Owners2.62%
Short Float %9.49%
Short Ratio8.32
XERS Industry Overview
XERS operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
34%
Outperformed 34% of sub-industries
3 Month Rank
52%
Outperformed 52% of sub-industries
6 Month Rank
39%
Outperformed 39% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 3.7%
- Average ROE
- 51.3%
- Average Profit Margin
- 27.9%
- Average Operating Margin
- 37.7%
- Average P/E
- 25.7
- Average Fwd P/E
- 17.9
- Average Debt/Equity
- 1.2
XERS Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 22.69 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 18.02 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.52 | 269.662B | ||
| PFE | PFIZER INC | 8.85 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.5 | 123.709B | ||
| ZTS | ZOETIS INC | 16.15 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.6 | 28.899B | ||
| VTRS | VIATRIS INC | 5.97 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.32 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 34.44 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XERS
Company Profile
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
Company Info
IPO: 2018-06-21
XERIS BIOPHARMA HOLDINGS INC
1375 West Fulton Street, Suite 1300
Chicago ILLINOIS 60601 US
CEO: Paul R. Edick
Employees: 435
Phone: 18444455704
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you describe the business of XERIS BIOPHARMA HOLDINGS INC?
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company is headquartered in Chicago, Illinois and currently employs 435 full-time employees. The company went IPO on 2018-06-21. The company has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. The company also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. The company is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.
What is the stock price of XERIS BIOPHARMA HOLDINGS INC today?
The current stock price of XERS is 6.285 USD. The price increased by 2.53% in the last trading session.
What is the dividend status of XERIS BIOPHARMA HOLDINGS INC?
XERS does not pay a dividend.
What is the ChartMill technical and fundamental rating of XERS stock?
XERS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the market capitalization of XERS stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a market capitalization of 1.08B USD. This makes XERS a Small Cap stock.
When does XERIS BIOPHARMA HOLDINGS INC (XERS) report earnings?
XERIS BIOPHARMA HOLDINGS INC (XERS) will report earnings on 2026-05-07.